Blood Work for Premature Menopause
For women under 40 with menstrual irregularities, order FSH, estradiol, hCG, and prolactin as the essential initial hormone panel, with FSH >25 IU/L on two occasions at least 4 weeks apart (with low estradiol) confirming the diagnosis of premature ovarian insufficiency (POI). 1
Initial Diagnostic Hormone Panel
When evaluating suspected POI in women under 40 with amenorrhea or oligomenorrhea lasting >4 months, the following tests are required:
Essential First-Line Tests
- hCG - to rule out pregnancy 1
- FSH - diagnostic threshold >25 IU/L 1
- Estradiol - should be low (typically <50 pmol/L) 2
- Prolactin - to exclude hyperprolactinemia 1
Critical caveat: If the patient is on combined oral contraceptives or progestins with antigonadotropic action, FSH will be falsely suppressed. Stop these medications and retest at least 3 months later 1.
Confirmation Testing
- Repeat FSH measurement at least 4 weeks after the first elevated result 1
- A single elevated FSH >25 IU/L may be sufficient if clinical context is clear, though confirmation strengthens diagnosis 3
- Low estradiol confirms the diagnosis is not being made during a pre-ovulation peak (when estradiol would be 150-200 pg/mL per mature follicle) 1
AMH Testing
- Anti-Müllerian hormone (AMH) can contribute to ovarian reserve assessment 1
- Very low or undetectable AMH supports the diagnosis, particularly in young women with family history of POI or those presenting with primary/secondary amenorrhea 4
- AMH is especially useful when there is diagnostic uncertainty 3
Etiological Work-Up
Once POI is confirmed, proceed with these tests to identify underlying causes:
Autoimmune Screening
- TSH - screen for thyroid dysfunction 1
- Anti-TPO antibodies - thyroid autoimmunity 1
- Anti-21-hydroxylase antibodies - screen for Addison's disease risk 1
- Screen clinically for other autoimmune conditions: diabetes, vitiligo, systemic lupus, rheumatoid arthritis, celiac disease 1
Genetic Testing
- Karyotype - especially important in women <30 years to detect chromosomal abnormalities (particularly X chromosome abnormalities) 1, 2
- FMR1 gene premutation screening - fragile X premutation 1
- Gene panel studies if initial testing is normal 1
Additional Assessments
Bone Health
- Bone mineral density (BMD) via osteodensitometry - POI significantly increases osteoporosis risk due to prolonged estrogen deficiency 1
- Reassess every 5 years if osteoporosis is diagnosed 1
Metabolic Screening
- Lipid profile - POI increases cardiovascular risk 2
- Consider glucose/HbA1c screening given increased metabolic risk
Important Clinical Pitfalls
Timing matters: Do not measure FSH during oral contraceptive use - it will be falsely low. Wait 3+ months after stopping 1
Single measurement limitations: FSH can fluctuate in POI, as ovarian function may be intermittent. This is why confirmation testing is recommended, though recent guidelines suggest one elevated value may suffice in clear cases 3
Age-specific FSH interpretation: FSH levels in autoimmune POI are often lower (25-35 IU/L) than in idiopathic POI (average 37 IU/L, range 26-64), so the diagnostic threshold has been lowered to >25 IU/L 1
Don't delay genetic testing: Karyotype should be performed in all women diagnosed before age 30, as chromosomal abnormalities are a significant cause 1, 2
Screen for polyendocrinopathy: 10-15% of POI cases have autoimmune etiology, and these women are at risk for multiple endocrine failures 2